Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.1.1.320 - type II protein arginine methyltransferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
Adenocarcinoma in Situ
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
Adenocarcinoma of Lung
An AKT/PRMT5/SREBP1 axis in lung adenocarcinoma regulates de novo lipogenesis and tumor growth.
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells.
Protein arginine methyltransferase 5 is essential for growth of lung cancer cells.
Protein arginine methyltransferase 5 mediates enolase-1 cell surface trafficking in human lung adenocarcinoma cells.
Adenoma
High nuclear expression of protein arginine methyltransferase-5 is a potentially useful marker to estimate submucosal invasion in endoscopically resected early colorectal carcinoma.
Alzheimer Disease
The protein arginine methyltransferase PRMT5 regulates A?-induced toxicity in human cells and Caenorhabditis elegans models of Alzheimer's disease.
Arthritis, Rheumatoid
Role of protein arginine methyltransferase 5 in inflammation and migration of fibroblast-like synoviocytes in rheumatoid arthritis.
Astrocytoma
Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.
Autoimmune Diseases
Protein arginine methyltransferase 5 promotes cholesterol biosynthesis-mediated Th17 responses and autoimmunity.
Bone Resorption
Inhibition of PRMT5 suppresses osteoclast differentiation and partially protects against ovariectomy-induced bone loss through downregulation of CXCL10 and RSAD2.
Brachydactyly
Expanding the clinical and molecular spectrum of PRMT7 mutations: three additional patients and review.
Further delineation of the phenotype caused by loss of function mutations in PRMT7.
Loss of the arginine methyltranserase PRMT7 causes syndromic intellectual disability with microcephaly and brachydactyly.
Breast Neoplasms
Arginine methylation of SHANK2 by PRMT7 promotes human breast cancer metastasis through activating endosomal FAK signalling.
Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer.
CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription.
Curcumin ameliorates PRMT5-MEP50 arginine methyltransferase expression by decreasing the Sp1 and NF-YA transcription factors in the A549 and MCF-7 cells.
Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer.
Examining Product Specificity in Protein Arginine Methyltransferase 7 (PRMT7) Using Quantum and Molecular Mechanical Simulations.
Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis.
Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?
LKB1 regulates PRMT5 activity in breast cancer.
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.
PRMT5 and FOXP1 expression profile in invasive breast cancer patients undergoing neoadjuvant chemotherapy.
PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression.
PRMT5 Promotes Aerobic Glycolysis and Invasion of Breast Cancer Cells by Regulating the LXR?/NF-?Bp65 Pathway.
PRMT7 induces epithelial-to-mesenchymal transition and promotes metastasis in breast cancer.
PRMT7 Methylates Eukaryotic Translation Initiation Factor 2? and Regulates its Role in Stress Granule Formation.
Proliferative role of TRAF4 in breast cancer by upregulating PRMT5 nuclear expression.
Protein arginine methyltransferase 5 (PRMT5) activates WNT/?-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3.
Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4.
Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression.
Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21CIP1 in human breast cancer cell lines.
Retraction: Arginine methylation of SHANK2 by PRMT7 promotes human breast cancer metastasis through activating endosomal FAK signalling.
Carcinogenesis
Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis.
Cell metabolic profiling of colorectal cancer via 1H NMR.
Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.
Expression of protein arginine methyltransferase-5 in oral squamous cell carcinoma and its significance in epithelial-to-mesenchymal transition.
Identification of a Novel Protein Arginine Methyltransferase 5 Inhibitor in Non-small Cell Lung Cancer by Structure-Based Virtual Screening.
Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis.
Lead induces the up-regulation of the protein arginine methyltransferase 5 possibly by its promoter demethylation.
Methylation of ribosomal protein S10 by protein-arginine methyltransferase 5 regulates ribosome biogenesis.
Methylation of tumor suppressor gene CDH13 and SHP1 promoters and their epigenetic regulation by the UHRF1/PRMT5 complex in endometrial carcinoma.
Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
PRMT5 dimethylates R30 of the p65 subunit to activate NF-?B.
PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis.
PRMT5 Promotes Aerobic Glycolysis and Invasion of Breast Cancer Cells by Regulating the LXR?/NF-?Bp65 Pathway.
PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma.
PRMT5 promotes epithelial-mesenchymal transition via EGFR-?-catenin axis in pancreatic cancer cells.
PRMT5 promotes progression of endometrioid adenocarcinoma via ER? and cell cycle signaling pathways.
PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells.
PRMT5-mediated H4R3sme2 confers cell differentiation in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia.
PRMT7 contributes to the metastasis phenotype in human non-small-cell lung cancer cells possibly through the interaction with HSPA5 and EEF2.
Promotion effect of microcystin-LR on liver tumor progression in krasV12 transgenic zebrafish following acute or subacute exposure.
Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/?-catenin and AKT/GSK3? proliferative signaling.
Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells.
Protein Arginine Methyltransferase 5 Functions via Interacting Proteins.
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.
Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells.
Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade.
Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosis.
Protein arginine methyltransferase 5 promotes cholesterol biosynthesis-mediated Th17 responses and autoimmunity.
Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation.
Proteomics profiling of arginine methylation defines PRMT5 substrate specificity.
Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
Role of protein arginine methyltransferase 5 in human cancers.
Selective small-chemical inhibitors of protein arginine methyltransferase 5 with anti-lung cancer activity.
Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription.
The methylation induced by protein arginine methyltransferase 5 promotes tumorigenesis and progression of lung cancer.
The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond.
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
Zebrafish prmt5 arginine methyltransferase is essential for germ cell development.
Carcinoma
Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer.
Correction: PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial-Mesenchymal Transition.
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
Expression of protein arginine methyltransferase-5 in oral squamous cell carcinoma and its significance in epithelial-to-mesenchymal transition.
High nuclear expression of protein arginine methyltransferase-5 is a potentially useful marker to estimate submucosal invasion in endoscopically resected early colorectal carcinoma.
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status.
PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial-Mesenchymal Transition.
PRMT5/Wnt4 axis promotes lymph-node metastasis and proliferation of laryngeal carcinoma.
PRMT7 promotes the growth of renal cell carcinoma through modulating the ?-catenin/C-MYC axis.
Protein Arginine Methyltransferase 5 Promotes Esophageal Squamous Cell Carcinoma Proliferation and Metastasis via LKB1/AMPK/mTOR Signaling Pathway.
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
Sulforaphane suppresses PRMT5/MEP50 function in epidermal squamous cell carcinoma leading to reduced tumor formation.
Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription.
The LINC01138 interacts with PRMT5 to promote SREBP1-mediated lipid desaturation and cell growth in clear cell renal cell carcinoma.
Carcinoma, Endometrioid
PRMT5 promotes progression of endometrioid adenocarcinoma via ER? and cell cycle signaling pathways.
Carcinoma, Hepatocellular
Myosin phosphatase and RhoA-activated kinase modulate arginine methylation by the regulation of protein arginine methyltransferase 5 in hepatocellular carcinoma cells.
PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.
PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma.
PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3?/Snail signalling.
Prognostic impact of SET domain-containing protein 8 and protein arginine methyltransferase 5 in patients with hepatocellular carcinoma following curative resection.
Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells.
S-adenosylmethionine:protein methyltransferases in hepatomas.
Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4?.
Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.
The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy.
The Role of the PRMT5-SND1 Axis in Hepatocellular Carcinoma.
Carcinoma, Non-Small-Cell Lung
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
Identification of a Novel Protein Arginine Methyltransferase 5 Inhibitor in Non-small Cell Lung Cancer by Structure-Based Virtual Screening.
Carcinoma, Ovarian Epithelial
Overexpression of PRMT5 Promotes Tumor Cell Growth and Is Associated with Poor Disease Prognosis in Epithelial Ovarian Cancer.
Carcinoma, Renal Cell
PRMT7 promotes the growth of renal cell carcinoma through modulating the ?-catenin/C-MYC axis.
The LINC01138 interacts with PRMT5 to promote SREBP1-mediated lipid desaturation and cell growth in clear cell renal cell carcinoma.
Carcinoma, Squamous Cell
Sulforaphane suppresses PRMT5/MEP50 function in epidermal squamous cell carcinoma leading to reduced tumor formation.
Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription.
Cardiomegaly
Histone H4R3 symmetric di-methylation by Prmt5 protects against cardiac hypertrophy via regulation of Filip1L/?-catenin.
Inhibition of cardiomyocyte hypertrophy by protein arginine methyltransferase 5.
PRMT5 Prevents Cardiomyocyte Hypertrophy via Symmetric Dimethylating HoxA9 and Repressing HoxA9 Expression.
Cardiomyopathy, Dilated
PRMT5 Prevents Dilated Cardiomyopathy via Suppression of Protein O-GlcNAcylation.
Cardiovascular Diseases
Artificial intelligence and leukocyte epigenomics: Evaluation and prediction of late-onset Alzheimer's disease.
Citrullinemia
PRMT7 Interacts with ASS1 and Citrullinemia Mutations Disrupt the Interaction.
Colitis
Protein Arginine Methyltransferase 5 Inhibition Upregulates Foxp3(+) Regulatory T Cells Frequency and Function during the Ulcerative Colitis.
Colitis, Ulcerative
Protein Arginine Methyltransferase 5 Inhibition Upregulates Foxp3(+) Regulatory T Cells Frequency and Function during the Ulcerative Colitis.
Colonic Neoplasms
Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells.
Colorectal Neoplasms
A Comprehensive Analysis of Symmetric Arginine Dimethylation in Colorectal Cancer Tissues Using Immunoaffinity Enrichment and Mass Spectrometry.
Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers.
Arginine methylation controls growth regulation by E2F-1.
Cell metabolic profiling of colorectal cancer via 1H NMR.
Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.
High nuclear expression of protein arginine methyltransferase-5 is a potentially useful marker to estimate submucosal invasion in endoscopically resected early colorectal carcinoma.
NAA40 contributes to colorectal cancer growth by controlling PRMT5 expression.
PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
PRMT5 promotes colorectal cancer growth by interaction with MCM7.
PRMT5 regulates colorectal cancer cell growth and EMT via EGFR/Akt/GSK3? signaling cascades.
Protein Arginine Methyltransferase 5 as a Therapeutic Target for KRAS Mutated Colorectal Cancer.
Regulation of a PRMT5/NF-?B Axis by Phosphorylation of PRMT5 at Serine 15 in Colorectal Cancer.
Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation.
Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
Communicable Diseases
Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Cryptorchidism
Loss of the arginine methyltranserase PRMT7 causes syndromic intellectual disability with microcephaly and brachydactyly.
Deltaretrovirus Infections
PRMT5 Is Required for Bovine Leukemia Virus Infection In Vivo and Regulates BLV Gene Expression, Syncytium Formation, and Glycosylation In Vitro.
Encephalomyelitis
Protein arginine methyltransferase 5 promotes cholesterol biosynthesis-mediated Th17 responses and autoimmunity.
Encephalomyelitis, Autoimmune, Experimental
Protein arginine methyltransferase 5 promotes cholesterol biosynthesis-mediated Th17 responses and autoimmunity.
Endometrial Hyperplasia
PRMT5 promotes progression of endometrioid adenocarcinoma via ER? and cell cycle signaling pathways.
Endometrial Neoplasms
PRMT5 promotes progression of endometrioid adenocarcinoma via ER? and cell cycle signaling pathways.
Endometriosis
Protein arginine methyltransferase 5 mediates THP-1-derived macrophage activation dependent on NF-?B in endometriosis.
Enzootic Bovine Leukosis
PRMT5 Is Required for Bovine Leukemia Virus Infection In Vivo and Regulates BLV Gene Expression, Syncytium Formation, and Glycosylation In Vitro.
Epstein-Barr Virus Infections
Arginine Methyltransferases Are Regulated by Epstein-Barr Virus in B Cells and Are Differentially Expressed in Hodgkin's Lymphoma.
Modulation of Epstein-Barr virus nuclear antigen 2-dependent transcription by protein arginine methyltransferase 5.
Protein Arginine Methyltransferase 5 Functions via Interacting Proteins.
Esophageal Squamous Cell Carcinoma
Protein Arginine Methyltransferase 5 Promotes Esophageal Squamous Cell Carcinoma Proliferation and Metastasis via LKB1/AMPK/mTOR Signaling Pathway.
Fanconi Anemia
Epigenetic regulation of Fanconi anemia genes implicates PRMT5 blockage as a strategy for tumor chemosensitization.
Fatty Liver
Inhibition of protein arginine methyltransferase 5 enhances hepatic mitochondrial biogenesis.
Genetic Diseases, Inborn
Novel PRMT7 mutation in a rare case of dysmorphism and intellectual disability.
Glioblastoma
A PRMT5-RNF168-SMURF2 Axis Controls H2AX Proteostasis.
Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.
Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma.
Identification of 5-benzylidene-2-phenylthiazolones as potent PRMT5 inhibitors by virtual screening, structural optimization and biological evaluations.
Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
Integrin ?v?3 Engagement Regulates Glucose Metabolism and Migration through Focal Adhesion Kinase (FAK) and Protein Arginine Methyltransferase 5 (PRMT5) in Glioblastoma Cells.
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.
Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells.
PRMT5 as a druggable target for glioblastoma therapy.
PRMT5 inhibition disrupts splicing and stemness in glioblastoma.
The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Glioma
Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.
LncRNA SNHG16 Functions as an Oncogene by Sponging MiR-4518 and Up-Regulating PRMT5 Expression in Glioma.
Long noncoding RNA LINC00515 promotes cell proliferation and inhibits apoptosis by sponging miR-16 and activating PRMT5 expression in human glioma.
Overexpression of HOXC10 promotes angiogenesis in human glioma via interaction with PRMT5 and upregulation of VEGFA expression.
Glucose Intolerance
Islet-Specific Prmt5 Excision Leads to Reduced Insulin Expression and Glucose Intolerance in Mice.
Graft vs Host Disease
PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease.
Head and Neck Neoplasms
Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status.
Hearing Loss
Further delineation of the phenotype caused by loss of function mutations in PRMT7.
Heart Diseases
Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Heart Failure
Inhibition of cardiomyocyte hypertrophy by protein arginine methyltransferase 5.
PRMT5 Prevents Dilated Cardiomyopathy via Suppression of Protein O-GlcNAcylation.
Hematologic Neoplasms
Identification of Selective, Cell Active Inhibitors of Protein Arginine Methyltransferase 5 through Structure-Based Virtual Screening and Biological Assays.
PRMT5 in gene regulation and hematologic malignancies.
PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma.
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
Hepatitis B
PRMT5 Restricts Hepatitis B Virus Replication via Epigenetic Repression of cccDNA Transcription and Interference with pgRNA Encapsidation.
PRMT5: A novel regulator of Hepatitis B virus replication and an arginine methylase of HBV core.
PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3?/Snail signalling.
Protein Arginine Methyltransferase 5 Functions via Interacting Proteins.
Hodgkin Disease
Arginine Methyltransferases Are Regulated by Epstein-Barr Virus in B Cells and Are Differentially Expressed in Hodgkin's Lymphoma.
Hypogonadism
Pituitary stalk interruption syndrome is characterized by genetic heterogeneity.
Infections
Arginine methyltransferase PRMT5 negatively regulates cGAS-mediated antiviral immune response.
Dual regulation of Arabidopsis AGO2 by arginine methylation.
PRMT5 Restricts Hepatitis B Virus Replication via Epigenetic Repression of cccDNA Transcription and Interference with pgRNA Encapsidation.
Protein Arginine N-methyltransferases 5 and 7 Promote HIV-1 Production.
Zebrafish prmt7 negatively regulates antiviral responses by suppressing the retinoic acid-inducible gene-I-like receptor signaling.
Infertility, Female
PRMT5 protects genomic integrity during global DNA demethylation in primordial germ cells and preimplantation embryos.
PRMT5>regulates ovarian follicle development by facilitating Wt1 translation.
Infertility, Male
PRMT5 Is Involved in Spermatogonial Stem Cells Maintenance by Regulating Plzf Expression via Modulation of Lysine Histone Modifications.
Intellectual Disability
Expanding the clinical and molecular spectrum of PRMT7 mutations: three additional patients and review.
Further delineation of the phenotype caused by loss of function mutations in PRMT7.
Loss of the arginine methyltranserase PRMT7 causes syndromic intellectual disability with microcephaly and brachydactyly.
Novel PRMT7 mutation in a rare case of dysmorphism and intellectual disability.
Laryngeal Neoplasms
PRMT5/Wnt4 axis promotes lymph-node metastasis and proliferation of laryngeal carcinoma.
Leukemia
Epigenetic control via allosteric regulation of mammalian protein arginine methyltransferases.
Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations.
Identification of Selective, Cell Active Inhibitors of Protein Arginine Methyltransferase 5 through Structure-Based Virtual Screening and Biological Assays.
Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9.
Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
PRMT5 in gene regulation and hematologic malignancies.
Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency.
PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia.
PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.
PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease.
PRMT5-mediated H4R3sme2 confers cell differentiation in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia.
PRMT5-mediated histone arginine methylation antagonizes transcriptional repression by polycomb complex PRC2.
Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells.
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.
The Fanconi anemia pathway controls oncogenic response in hematopoietic stem and progenitor cells by regulating PRMT5-mediated p53 arginine methylation.
The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.
Leukemia, Erythroblastic, Acute
CARM1-mediated methylation of protein arginine methyltransferase 5 represses human ?-globin gene expression in erythroleukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Genomic deregulation of PRMT5 supports growth and stress tolerance in chronic lymphocytic leukemia.
Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Leukemia, Myeloid, Acute
Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia.
PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.
The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.
Leukemia-Lymphoma, Adult T-Cell
PRMT5 Is Upregulated in HTLV-1-Mediated T-Cell Transformation and Selective Inhibition Alters Viral Gene Expression and Infected Cell Survival.
Leukocytosis
PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN.
Lipodystrophy
Protein Arginine Methyltransferase PRMT5 Regulates Fatty Acid Metabolism and Lipid Droplet Biogenesis in White Adipose Tissues.
Lipodystrophy, Congenital Generalized
Protein Arginine Methyltransferase PRMT5 Regulates Fatty Acid Metabolism and Lipid Droplet Biogenesis in White Adipose Tissues.
Lung Neoplasms
Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer.
GLI pathogenesis-related 1 functions as a tumor-suppressor in lung cancer.
Identification of a Novel Protein Arginine Methyltransferase 5 Inhibitor in Non-small Cell Lung Cancer by Structure-Based Virtual Screening.
PRMT1 loss sensitizes cells to PRMT5 inhibition.
PRMT5 Enables Robust STAT3 Activation via Arginine Symmetric Dimethylation of SMAD7.
PRMT5 Promotes EMT Through Regulating Akt Activity in Human Lung Cancer.
PRMT5 Promotes Human Lung Cancer Cell Apoptosis via Akt/Gsk3? Signaling Induced by Resveratrol.
PRMT5 promotes inflammation of cigarette smoke extract-induced bronchial epithelial cells by up-regulation of CXCL10.
PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells.
PRMT7 contributes to the metastasis phenotype in human non-small-cell lung cancer cells possibly through the interaction with HSPA5 and EEF2.
Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade.
Protein arginine methyltransferase 5 is essential for growth of lung cancer cells.
Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling.
Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation.
Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth.
The arginine methyltransferase PRMT5 and PRMT1 distinctly regulate the degradation of anti-apoptotic protein CFLARL in human lung cancer cells.
The methylation induced by protein arginine methyltransferase 5 promotes tumorigenesis and progression of lung cancer.
Lymphatic Metastasis
PRMT5/Wnt4 axis promotes lymph-node metastasis and proliferation of laryngeal carcinoma.
Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer.
Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling.
Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression.
Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription.
Lymphoma
Epigenetic control via allosteric regulation of mammalian protein arginine methyltransferases.
Histone Arginine Methylation by PRMT7 Controls Germinal Center Formation via Regulating Bcl6 Transcription.
Identification of 5-benzylidene-2-phenylthiazolones as potent PRMT5 inhibitors by virtual screening, structural optimization and biological evaluations.
Identification of Selective, Cell Active Inhibitors of Protein Arginine Methyltransferase 5 through Structure-Based Virtual Screening and Biological Assays.
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma.
Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase.
Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
PRMT5 in gene regulation and hematologic malignancies.
PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.
PRMT5 is essential for B cell development and germinal center dynamics.
PRMT5 Is Required for Bovine Leukemia Virus Infection In Vivo and Regulates BLV Gene Expression, Syncytium Formation, and Glycosylation In Vitro.
PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.
Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/?-catenin and AKT/GSK3? proliferative signaling.
Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.
Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells.
Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
Lymphoma, B-Cell
PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.
PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.
Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.
Lymphoma, Large B-Cell, Diffuse
PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
Lymphoma, Mantle-Cell
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma.
Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
Lymphoma, Non-Hodgkin
Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/?-catenin and AKT/GSK3? proliferative signaling.
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
Medulloblastoma
Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Melanoma
BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases.
Expression of proteins involved in epigenetic regulation in human cutaneous melanoma and peritumoral skin.
Hypoxia-Induced Adaptations of miRNomes and Proteomes in Melanoma Cells and Their Secreted Extracellular Vesicles.
PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity.
PRMT5 Is Upregulated in Malignant and Metastatic Melanoma and Regulates Expression of MITF and p27(Kip1.)
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
Shank-associated RH domain interactor signaling in tumorigenesis.
SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth.
Mesothelioma
PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach.
Sulforaphane inhibits PRMT5 and MEP50 function to suppress the mesothelioma cancer cell phenotype.
Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression.
Mesothelioma, Malignant
Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression.
Metabolic Diseases
Inhibition of protein arginine methyltransferase 5 enhances hepatic mitochondrial biogenesis.
Microcephaly
Loss of the arginine methyltranserase PRMT7 causes syndromic intellectual disability with microcephaly and brachydactyly.
Multiple Myeloma
PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma.
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.
Muscle Hypotonia
PRMT7 as a unique member of the protein arginine methyltransferase family: A review.
Muscular Atrophy, Spinal
SMN and symmetric arginine dimethylation of RNA polymerase II C-terminal domain control termination.
Myocardial Infarction
Low expression of PRMT5 in peripheral blood may serve as a potential independent risk factor in assessments of the risk of stable CAD and AMI.
Neoplasm Metastasis
A TGF?-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.
Arginine methylation of SHANK2 by PRMT7 promotes human breast cancer metastasis through activating endosomal FAK signalling.
CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription.
Correction: PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial-Mesenchymal Transition.
Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis.
Metadherin-PRMT5 complex enhances the metastasis of hepatocellular carcinoma through the WNT-?-catenin signaling pathway.
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
MiR-1266 suppresses the growth and metastasis of prostate cancer via targeting PRMT5.
PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial-Mesenchymal Transition.
PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.
PRMT5/Wnt4 axis promotes lymph-node metastasis and proliferation of laryngeal carcinoma.
PRMT7 as a unique member of the protein arginine methyltransferase family: A review.
PRMT7 contributes to the metastasis phenotype in human non-small-cell lung cancer cells possibly through the interaction with HSPA5 and EEF2.
PRMT7 induces epithelial-to-mesenchymal transition and promotes metastasis in breast cancer.
PRMT7 Interacts with ASS1 and Citrullinemia Mutations Disrupt the Interaction.
PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3?/Snail signalling.
Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer.
Protein Arginine Methyltransferase 5 Promotes Esophageal Squamous Cell Carcinoma Proliferation and Metastasis via LKB1/AMPK/mTOR Signaling Pathway.
Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling.
Protein arginine methyltransferase 5-mediated epigenetic silencing of IRX1 contributes to tumorigenicity and metastasis of gastric cancer.
Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression.
Retraction: Arginine methylation of SHANK2 by PRMT7 promotes human breast cancer metastasis through activating endosomal FAK signalling.
Snail/PRMT5/NuRD complex contributes to DNA hypermethylation in cervical cancer by TET1 inhibition.
Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription.
The methylation induced by protein arginine methyltransferase 5 promotes tumorigenesis and progression of lung cancer.
Neoplasm, Residual
Overexpression of PRMT5 Promotes Tumor Cell Growth and Is Associated with Poor Disease Prognosis in Epithelial Ovarian Cancer.
Neoplasms
A Comprehensive Analysis of Symmetric Arginine Dimethylation in Colorectal Cancer Tissues Using Immunoaffinity Enrichment and Mass Spectrometry.
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.
Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers.
Aflatoxin-induced upregulation of protein arginine methyltransferase 5 is mediated by protein kinase C and extracellular signal-regulated kinase.
Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5).
An AKT/PRMT5/SREBP1 axis in lung adenocarcinoma regulates de novo lipogenesis and tumor growth.
Anguilla japonica lectin 1 delivery through adenovirus vector induces apoptotic cancer cell death through interaction with PRMT5.
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Arginine Methylation of SREBP1a via PRMT5 Promotes De Novo Lipogenesis and Tumor Growth.
Arginine methyltransferase inhibitor 1 exhibits antitumor effects against cervical cancer in vitro and in vivo.
AS1411 Alters the Localization of a Complex Containing Protein Arginine Methyltransferase 5 and Nucleolin.
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.
Cell metabolic profiling of colorectal cancer via 1H NMR.
Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma.
Coronin 2A (CRN5) expression is associated with colorectal adenoma-adenocarcinoma sequence and oncogenic signalling.
Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.
Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening.
Discovery of a Dual PRMT5-PRMT7 Inhibitor.
Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction.
Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders.
Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.
Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations.
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer.
Enhanced arginine methylation of programmed cell death 4 protein during nutrient deprivation promotes tumor cell viability.
Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways.
Epigenetic regulation of Fanconi anemia genes implicates PRMT5 blockage as a strategy for tumor chemosensitization.
EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma.
Esophageal Squamous Cell Carcinoma Is Accompanied by Local and Systemic Changes in L-arginine/NO Pathway.
Exploiting the Hidden Treasure of Detained Introns.
Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
Expression of protein arginine methyltransferase-5 in oral squamous cell carcinoma and its significance in epithelial-to-mesenchymal transition.
Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma.
GLI pathogenesis-related 1 functions as a tumor-suppressor in lung cancer.
High PRMT5 expression is associated with poor overall survival and tumor progression in bladder cancer.
HiJAKing the methylosome in myeloproliferative disorders.
HOXA9 Methylation by PRMT5 Is Essential for Endothelial Cell Expression of Leukocyte Adhesion Molecules.
Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes.
Hypoxia-Induced Adaptations of miRNomes and Proteomes in Melanoma Cells and Their Secreted Extracellular Vesicles.
Identification of protein arginine N-methyltransferase 5 (PRMT5) as a novel interacting protein with the tumor suppressor protein RASSF1A.
Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
Inhibition of PRMT5 suppresses osteoclast differentiation and partially protects against ovariectomy-induced bone loss through downregulation of CXCL10 and RSAD2.
L-Arginine/Nitric Oxide Pathway Is Altered in Colorectal Cancer and Can Be Modulated by Novel Derivatives from Oxicam Class of Non-Steroidal Anti-Inflammatory Drugs.
Late Cornified Envelope Group I, a novel target of p53, regulates PRMT5 activity.
Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?
LKB1 regulates PRMT5 activity in breast cancer.
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.
Long noncoding RNA FOXD2-AS1 enhances chemotherapeutic resistance of laryngeal squamous cell carcinoma via STAT3 activation.
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma.
M-TAP Dance: Targeting PRMT1 and PRMT5 Family Members to Push Cancer Cells Over the Edge.
MEP50/PRMT5-mediated methylation activates GLI1 in Hedgehog signalling through inhibition of ubiquitination by the ITCH/NUMB complex.
Methylosome protein 50 promotes androgen- and estrogen-independent tumorigenesis.
Molecular basis for substrate recruitment to the PRMT5 methylosome.
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
MTAP Deletion Promotes Cancer-Cell Dependence on PRMT5.
MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
NAA40 contributes to colorectal cancer growth by controlling PRMT5 expression.
Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2low ATL and various cancer cells.
Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase.
Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status.
Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors.
Overexpression of PRMT5 Promotes Tumor Cell Growth and Is Associated with Poor Disease Prognosis in Epithelial Ovarian Cancer.
Pan-methylarginine antibody generation using PEG linked GAR motifs as antigens.
Pancreatic cancer organoids recapitulate disease and allow personalized drug screening.
Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
Prenatal and postnatal presentation of PRMT7 related syndrome: Expanding the phenotypic manifestations.
PRMT1 loss sensitizes cells to PRMT5 inhibition.
PRMT5 and FOXP1 expression profile in invasive breast cancer patients undergoing neoadjuvant chemotherapy.
PRMT5 and Tip60 Modify FOXP3 Function in Tumor Immunity.
PRMT5 Associates With the FOXP3 Homomer and When Disabled Enhances Targeted p185erbB2/neu Tumor Immunotherapy.
PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.
PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity.
PRMT5 Cooperates with pICln to Function as a Master Epigenetic Activator of DNA Double-Strand Break Repair Genes.
PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
PRMT5 dimethylates R30 of the p65 subunit to activate NF-?B.
PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.
PRMT5 Enables Robust STAT3 Activation via Arginine Symmetric Dimethylation of SMAD7.
PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis.
PRMT5 function and targeting in cancer.
PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
PRMT5 in gene regulation and hematologic malignancies.
PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN.
PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression.
PRMT5 is required for cell-cycle progression and p53 tumor suppressor function.
PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
PRMT5 Is Upregulated in Malignant and Metastatic Melanoma and Regulates Expression of MITF and p27(Kip1.)
PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia.
PRMT5 Modulates Splicing for Genome Integrity and Preserves Proteostasis of Hematopoietic Stem Cells.
PRMT5 prognostic value in cancer.
PRMT5 Promotes Aerobic Glycolysis and Invasion of Breast Cancer Cells by Regulating the LXR?/NF-?Bp65 Pathway.
PRMT5 promotes cancer cell migration and invasion through the E2F pathway.
PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma.
PRMT5 promotes colorectal cancer growth by interaction with MCM7.
PRMT5 Promotes EMT Through Regulating Akt Activity in Human Lung Cancer.
PRMT5 promotes epithelial-mesenchymal transition via EGFR-?-catenin axis in pancreatic cancer cells.
PRMT5 Promotes Human Lung Cancer Cell Apoptosis via Akt/Gsk3? Signaling Induced by Resveratrol.
PRMT5 promotes progression of endometrioid adenocarcinoma via ER? and cell cycle signaling pathways.
PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma.
PRMT5 regulates colorectal cancer cell growth and EMT via EGFR/Akt/GSK3? signaling cascades.
PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.
PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach.
PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation.
PRMT5-dependent p53 escape in tumorigenesis.
PRMT5-mediated methylation of YBX1 regulates NF-?B activity in colorectal cancer.
PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells.
PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis.
PRMT5-TRIM21 interaction regulates the senescence of osteosarcoma cells by targeting the TXNIP/p21 axis.
PRMT5/Wnt4 axis promotes lymph-node metastasis and proliferation of laryngeal carcinoma.
PRMT5: a putative oncogene and therapeutic target in prostate cancer.
PRMT7 as a unique member of the protein arginine methyltransferase family: A review.
PRMT7 induces epithelial-to-mesenchymal transition and promotes metastasis in breast cancer.
PRMT7 Interacts with ASS1 and Citrullinemia Mutations Disrupt the Interaction.
PRMT7 promotes the growth of renal cell carcinoma through modulating the ?-catenin/C-MYC axis.
PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3?/Snail signalling.
Profiling PRMT methylome reveals roles of hnRNPA1 arginine methylation in RNA splicing and cell growth.
Prognostic impact of SET domain-containing protein 8 and protein arginine methyltransferase 5 in patients with hepatocellular carcinoma following curative resection.
Proliferative role of TRAF4 in breast cancer by upregulating PRMT5 nuclear expression.
Promotion effect of microcystin-LR on liver tumor progression in krasV12 transgenic zebrafish following acute or subacute exposure.
Protein arginine methyltransferase 5 (PRMT5) activates WNT/?-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3.
Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer.
Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer.
Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/?-catenin and AKT/GSK3? proliferative signaling.
Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4.
Protein Arginine Methyltransferase 5 as a Therapeutic Target for KRAS Mutated Colorectal Cancer.
Protein arginine methyltransferase 5 catalyzes substrate dimethylation in a distributive fashion.
Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells.
Protein Arginine Methyltransferase 5 Functions via Interacting Proteins.
Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells.
Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade.
Protein arginine methyltransferase 5 is an essential component of the hypoxia-inducible factor 1 signaling pathway.
Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer.
Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells.
Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosis.
Protein Arginine Methyltransferase 5 Promotes Esophageal Squamous Cell Carcinoma Proliferation and Metastasis via LKB1/AMPK/mTOR Signaling Pathway.
Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling.
Protein arginine methyltransferase 5 promotes pICln-dependent androgen receptor transcription in castration-resistant prostate cancer.
Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation.
Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.
Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells.
Protein arginine methyltransferase 5-mediated epigenetic silencing of IRX1 contributes to tumorigenicity and metastasis of gastric cancer.
Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Protein arginine methyltransferase 5: a potential cancer therapeutic target.
Protein Arginine Methyltransferase PRMT5 Regulates Fatty Acid Metabolism and Lipid Droplet Biogenesis in White Adipose Tissues.
Proteomics profiling of arginine methylation defines PRMT5 substrate specificity.
Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
RIOK1 kinase activity is required for cell survival irrespective of MTAP status.
Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Role of protein arginine methyltransferase 5 in human cancers.
Selective PRMT5 Inhibitors Suppress Human CD8+ T Cells by Upregulation of p53 and Impairment of the AKT Pathway Similar to the Tumor Metabolite MTA.
Selective small-chemical inhibitors of protein arginine methyltransferase 5 with anti-lung cancer activity.
SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth.
Sirtuin 7-mediated deacetylation of WD repeat domain 77 (WDR77) suppresses cancer cell growth by reducing WDR77/PRMT5 transmethylase complex activity.
Snail/PRMT5/NuRD complex contributes to DNA hypermethylation in cervical cancer by TET1 inhibition.
Stochastic modulation evidences a transitory EGF-Ras-ERK MAPK activity induced by PRMT5.
Sulforaphane inhibits PRMT5 and MEP50 function to suppress the mesothelioma cancer cell phenotype.
Sulforaphane suppresses PRMT5/MEP50 function in epidermal squamous cell carcinoma leading to reduced tumor formation.
Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells.
Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription.
Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4?.
Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth.
Targeting protein arginine methyltransferase 5 in disease.
Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.
Targeting the transcription cycle and RNA processing in cancer treatment.
The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer.
The E3 ubiquitin ligase CHIP mediates ubiquitination and proteasomal degradation of PRMT5.
The expression and function of androgen receptor coactivator p44 and protein arginine methyltransferase 5 in the developing testis and testicular tumors.
The methylation induced by protein arginine methyltransferase 5 promotes tumorigenesis and progression of lung cancer.
The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond.
The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer.
The Proteins Interacting with Prmt5 in Medaka (Oryzias latipes) Identified by Yeast Two-Hybridization.
The Role of the PRMT5-SND1 Axis in Hepatocellular Carcinoma.
The Sm protein methyltransferase PRMT5 is not required for primordial germ cell specification in mice.
The Structure and Function of the PRMT5:MEP50 Complex.
The uncharacterized protein FAM47E interacts with PRMT5 and regulates its functions.
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.
Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells.
Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression.
Transition state analogue of MTAP extends lifespan of APCMin/+ mice.
Tumor necrosis factor (TNF)-? induction of CXCL10 in endothelial cells requires protein arginine methyltransferase 5 (PRMT5)-mediated nuclear factor (NF)-?B p65 methylation.
Neuroblastoma
Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells.
Nevus, Pigmented
PRMT5 Is Upregulated in Malignant and Metastatic Melanoma and Regulates Expression of MITF and p27(Kip1.)
Obesity
Examining Product Specificity in Protein Arginine Methyltransferase 7 (PRMT7) Using Quantum and Molecular Mechanical Simulations.
Prmt7 Deficiency Causes Reduced Skeletal Muscle Oxidative Metabolism and Age-Related Obesity.
Osteoarthritis
PRMT5 inhibition attenuates cartilage degradation by reducing MAPK and NF-?B signaling.
Osteosarcoma
MiRNA-543 promotes osteosarcoma cell proliferation and glycolysis by partially suppressing PRMT9 and stabilizing HIF-1? protein.
Ovarian Neoplasms
Overexpression of PRMT5 Promotes Tumor Cell Growth and Is Associated with Poor Disease Prognosis in Epithelial Ovarian Cancer.
Pancreatic Neoplasms
PRMT1 loss sensitizes cells to PRMT5 inhibition.
PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis.
PRMT5 promotes epithelial-mesenchymal transition via EGFR-?-catenin axis in pancreatic cancer cells.
Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells.
Paralysis
The protein arginine methyltransferase PRMT5 regulates A?-induced toxicity in human cells and Caenorhabditis elegans models of Alzheimer's disease.
Periodontitis
PRMT5 inhibition modulates murine dendritic cells activation by inhibiting the metabolism switch: a new therapeutic target in periodontitis.
Polycythemia Vera
PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PRMT5-mediated H4R3sme2 confers cell differentiation in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia.
Primary Myelofibrosis
PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN.
Prostatic Hyperplasia
Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
Prostatic Neoplasms
AS1411 Alters the Localization of a Complex Containing Protein Arginine Methyltransferase 5 and Nucleolin.
ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor.
MiR-1266 suppresses the growth and metastasis of prostate cancer via targeting PRMT5.
PRMT5 prognostic value in cancer.
PRMT5: a putative oncogene and therapeutic target in prostate cancer.
Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells.
Protein arginine methyltransferase 5 promotes pICln-dependent androgen receptor transcription in castration-resistant prostate cancer.
Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation.
The E3 ubiquitin ligase CHIP mediates ubiquitination and proteasomal degradation of PRMT5.
Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells.
Pseudohypoparathyroidism
Further delineation of the phenotype caused by loss of function mutations in PRMT7.
Pulmonary Disease, Chronic Obstructive
PRMT5 promotes inflammation of cigarette smoke extract-induced bronchial epithelial cells by up-regulation of CXCL10.
Reperfusion Injury
Human PRMT5 expression is enhanced during in vitro tubule formation and after in vivo ischemic injury in renal epithelial cells.
Inhibition of PRMT5 Attenuates Oxidative Stress-Induced Pyroptosis via Activation of the Nrf2/HO-1 Signal Pathway in a Mouse Model of Renal Ischemia-Reperfusion Injury.
Retinoblastoma
EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma.
PRMT5 Promotes Cyclin E1 and Cell Cycle Progression in CD4 Th1 Cells and Correlates With EAE Severity.
PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells.
Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade.
Sarcoma
Arginine methyltransferase inhibitor-1 inhibits sarcoma viability in vitro and in vivo.
Scoliosis
Regulation of terminal hypertrophic chondrocyte differentiation in Prmt5 mutant mice modeling infantile idiopathic scoliosis.
Seizures
Loss of the arginine methyltranserase PRMT7 causes syndromic intellectual disability with microcephaly and brachydactyly.
Seminoma
The expression and function of androgen receptor coactivator p44 and protein arginine methyltransferase 5 in the developing testis and testicular tumors.
Small Cell Lung Carcinoma
PRMT1 loss sensitizes cells to PRMT5 inhibition.
Squamous Cell Carcinoma of Head and Neck
Expression of protein arginine methyltransferase-5 in oral squamous cell carcinoma and its significance in epithelial-to-mesenchymal transition.
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status.
Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription.
Stomach Neoplasms
Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5.
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.
PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression.
Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer.
Protein arginine methyltransferase 5-mediated epigenetic silencing of IRX1 contributes to tumorigenicity and metastasis of gastric cancer.
Substrate specificity, processivity, and kinetic mechanism of protein arginine methyltransferase 5.
Teratoma
PRMT5 is Required for Human Embryonic Stem Cell Proliferation But Not Pluripotency.
Testicular Neoplasms
The expression and function of androgen receptor coactivator p44 and protein arginine methyltransferase 5 in the developing testis and testicular tumors.
Triple Negative Breast Neoplasms
Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer.
Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
type ii protein arginine methyltransferase deficiency
Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma.
Methylation determines the extracellular calcium sensitivity of the leak channel NALCN in hippocampal dentate granule cells.
PRMT5 is required for cell-cycle progression and p53 tumor suppressor function.
PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
PRMT7 deficiency causes dysregulation of the HCN channels in the CA1 pyramidal cells and impairment of social behaviors.
Prmt7 Deficiency Causes Reduced Skeletal Muscle Oxidative Metabolism and Age-Related Obesity.
PRMT7 deficiency enhances adipogenesis through modulation of C/EBP-?.
Structure and Function of Protein Arginine Methyltransferase PRMT7.
Urinary Bladder Neoplasms
High PRMT5 expression is associated with poor overall survival and tumor progression in bladder cancer.
Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosis.
Uterine Cervical Neoplasms
Arginine methyltransferase inhibitor 1 exhibits antitumor effects against cervical cancer in vitro and in vivo.
Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways.
PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.
Snail/PRMT5/NuRD complex contributes to DNA hypermethylation in cervical cancer by TET1 inhibition.
Viremia
Zebrafish prmt7 negatively regulates antiviral responses by suppressing the retinoic acid-inducible gene-I-like receptor signaling.
Virus Diseases
Arginine monomethylation by PRMT7 controls MAVS-mediated antiviral innate immunity.
Nuclear cGAS Functions Non-canonically to Enhance Antiviral Immunity via Recruiting Methyltransferase Prmt5.
PRMT5 Is Required for Bovine Leukemia Virus Infection In Vivo and Regulates BLV Gene Expression, Syncytium Formation, and Glycosylation In Vitro.
Wilms Tumor
Transcriptomic Analyses of MYCN-Regulated Genes in Anaplastic Wilms' Tumour Cell Lines Reveals Oncogenic Pathways and Potential Therapeutic Vulnerabilities.